Literature DB >> 7642209

Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1.

Z Prohászka1, T Hidvégi, E Ujhelyi, H Stoiber, M P Dierich, C Süsal, G Füst.   

Abstract

Previously we have investigated the interaction of human complement as well as one polyclonal and three human monoclonal antibody preparations with the human immunodeficiency virus type-1 (HIV-1) transmembrane recombinant glycoprotein (rgp41). A strong competition was found between the antibodies and deposited complement proteins for the same binding sites located within the immunodominant region of rgp41. The aim of the present experiments was to see if the same type of antibody-complement-HIV-1 interactions could be observed with the outer envelope glycoprotein (rgp120) of HIV-1. Three different glycosylated rgp120 preparations, as well as a synthetic peptide corresponding to the V3 loop of the MN strain, were adsorbed to enzyme-linked immunosorbent assay (ELISA) plates and incubated with mixtures of anti-rgp120 antibodies and normal human serum (NHS) as a complement source. Fixed complement proteins and antibodies were detected with specific, peroxidase-labelled antibodies against different complement proteins (C1q, C4b, C3b) and the gamma-chain of antibodies. In the absence of anti-rgp120, high amounts of C3 were deposited to each rgp120 preparation tested (including the V3 peptide) but significant differences in the amounts of bound C1q and C4b were observed. Using sera deficient in different complement proteins, we found that both the classical and the alternative pathways contributed to the C3 binding to rgp120. Addition of specific antibodies did not increase complement activation by rgp120 and only in the case of a monoclonal antibody to the V3-loop could we see complement-dependent inhibition of antibody binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642209      PMCID: PMC1383879     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  Complement activation decreases the ability of HIV transmembrane envelope protein to bind to specific antibody.

Authors:  F el Jarrah; T Hidvégi; E Ujhelyi; G Gyapay; V Salavecz; J J Origer; S Hollán; G Füst
Journal:  AIDS       Date:  1992-09       Impact factor: 4.177

2.  Prevention of HIV infection by passive immunization with HIV immunoglobulin.

Authors:  A M Prince; H Reesink; D Pascual; B Horowitz; I Hewlett; K K Murthy; K E Cobb; J W Eichberg
Journal:  AIDS Res Hum Retroviruses       Date:  1991-12       Impact factor: 2.205

3.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

4.  HIV and HIV-infected cells differentially activate the human complement system independent of antibody.

Authors:  B M Sölder; T F Schulz; P Hengster; J Löwer; C Larcher; G Bitterlich; R Kurth; H Wachter; M P Dierich
Journal:  Immunol Lett       Date:  1989-08       Impact factor: 3.685

5.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Authors:  G J LaRosa; J P Davide; K Weinhold; J A Waterbury; A T Profy; J A Lewis; A J Langlois; G R Dreesman; R N Boswell; P Shadduck
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

6.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.

Authors:  J Y Xu; M K Gorny; T Palker; S Karwowska; S Zolla-Pazner
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.

Authors:  A M Prince; B Horowitz; L Baker; R W Shulman; H Ralph; J Valinsky; A Cundell; B Brotman; W Boehle; F Rey
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

8.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

9.  Complement activation by human monoclonal antibodies to human immunodeficiency virus.

Authors:  G T Spear; D M Takefman; B L Sullivan; A L Landay; S Zolla-Pazner
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.

Authors:  C F Ebenbichler; N M Thielens; R Vornhagen; P Marschang; G J Arlaud; M P Dierich
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  10 in total

1.  Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers.

Authors:  D R Anderson; C M Carthy; J E Wilson; D Yang; D V Devine; B M McManus
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.

Authors:  R Herrero; L M Real; A Rivero-Juárez; J A Pineda; Á Camacho; J Macías; M Laplana; P Konieczny; F J Márquez; J C Souto; J M Soria; I Saulle; S Lo Caputo; M Biasin; A Rivero; J Fibla; A Caruz
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

Review 3.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

4.  Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.

Authors:  Zoltán Prohászka; Ferenc D Tóth; Dénes Bánhegyi; George Füst
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

5.  Heat shock protein 70 is a potent activator of the human complement system.

Authors:  Zoltán Prohászka; Mahavir Singh; Kálmán Nagy; Emese Kiss; Gabriella Lakos; Jenö Duba; George Füst
Journal:  Cell Stress Chaperones       Date:  2002-01       Impact factor: 3.667

Review 6.  In the Crosshairs: RNA Viruses OR Complement?

Authors:  Nisha Asok Kumar; Umerali Kunnakkadan; Sabu Thomas; John Bernet Johnson
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

7.  CD46 Genetic Variability and HIV-1 Infection Susceptibility.

Authors:  Carmen Serrano-Rísquez; Mohamed Omar; María Amparo Gómez-Vidal; Luis Miguel Real; Juan Antonio Pineda; Antonio Rivero; Antonio Rivero-Juárez; Donald Forthal; Francisco J Márquez; Sergio Lo Caputo; Mario Clerici; Mara Biasin; Antonio Caruz
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

8.  HIV-1 Trans Infection via TNTs Is Impeded by Targeting C5aR.

Authors:  Giulia Bertacchi; Wilfried Posch; Doris Wilflingseder
Journal:  Biomolecules       Date:  2022-02-15

Review 9.  Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development.

Authors:  Zoltán Beck; Zoltán Prohászka; George Füst
Journal:  Vaccine       Date:  2008-01-10       Impact factor: 3.641

10.  HIV-1 subverts the complement system in semen to enhance viral transmission.

Authors:  Bernadien M Nijmeijer; Marta Bermejo-Jambrina; Doris Wilflingseder; Teunis B H Geijtenbeek; Tanja M Kaptein; Carla M S Ribeiro
Journal:  Mucosal Immunol       Date:  2021-02-10       Impact factor: 7.313

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.